Breast cancer is stratified into distinct molecular subtypes, including Luminal A, Luminal B, HER2-positive, and triple-negative breast cancer (TNBC), each exhibiting divergent responses to therapeutic interventions, thereby underscoring the imperative for tailored treatment modalities such as chemotherapy, hormonal therapies, targeted therapies, and immunotherapies (Figure 1). This evidence concerns the gene ERBB2 and breast carcinoma.